UBC Faculty Research and Publications

Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5 Olson, Robert; Liu, Mitchell; Bergman, Alanah; Lam, Sonya; Hsu, Fred; Mou, Benjamin; Berrang, Tanya; Mestrovic, Ante; Chng, Nick; Hyde, Derek; Matthews, Quinn; Lund, Chad; Glick, Daniel; Pai, Howard; Basran, Parminder; Carolan, Hannah; Valev, Boris; Lefresene, Shilo; Tyldesley, Scott; Schellenberg, Devin


Background: Oligometastases refer to a state of disease where cancer has spread beyond the primary site, but is not yet widely metastatic, often defined as 1–3 or 1–5 metastases in number. Stereotactic ablative radiotherapy (SABR) is an emerging radiotherapy technique to treat oligometastases that require further prospective population-based toxicity estimates. Methods: This is a non-randomized phase II trial where all participants will receive experimental SABR treatment to all sites of newly diagnosed or progressing oligometastatic disease. We will accrue 200 patients to assess toxicity associated with this experimental treatment. The study was powered to give a 95% confidence on the risk of late grade 4 toxicity, anticipating a 

Item Media

Item Citations and Data


Attribution 4.0 International (CC BY 4.0)

Usage Statistics